To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those ...

Arexvy is a vaccine given to help prevent certain infections caused by respiratory syncytial virus (RSV) in adults ages 60 years and older. Arexvy is given as an injection into a muscle. Arexvy is a ...

NHL fans displeased with Wayne Gretzky's new commercial for AREXVY vaccine. (Image Source: Imagn). NHL fans have expressed their dissatisfaction on social media regarding Wayne Gretzky's latest ...

Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known interactions ...

GSK's Q3 2023 financials show strong performance, driven by Arexvy's sales; vigilance on broader market movements needed. Solid financials with improved FY guidance; liquidity constraints exist with a ...

What Is Arexvy, and Why Does It Matter? Arexvy is a vaccine that helps protect against serious lung illness caused by respiratory syncytial virus (RSV). The FDA has expanded its use to include people ...

Arexvy was approved in Europe in June 2023 for use in adults aged 60 and older for the prevention of lower respiratory tract disease (LRTD) caused by RSV. GSK’s vaccine Arexvy is currently undergoing ...

Besides Pfizer’s fast-declining COVID-19 sales, vaccine rival GSK is giving the New York drugmaker another reason to worry. In the first round of their RSV vaccine showdown, GSK’s Arexvy pulled down ...

The US has approved the first vaccine for respiratory syncytial virus (RSV) for people aged 60 and over. On Wednesday the Food and Drug Administration (FDA) approved the use of Arexvy in the country.

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the ...